Carol Patterson was waiting for a call from her doctor. When the phone rang on that afternoon in August 2011 at her home in Cortland, Ohio, it wasn’t a physician on the other end. A woman named Robin said she was representing the American Diabetes Association.
Merck & Co., Novo Nordisk A/S and other makers of popular treatments for diabetes may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.
A decade of work by scientists to create an artificial pancreas that will independently control insulin levels in people with Type 1 diabetes took a leap forward in research from Medtronic Inc. and Johnson & Johnson.
Medtronic Inc.’s advanced insulin pump can safely shut itself off when a patient’s blood sugar gets too low, according to a study hailed as breakthrough in the effort to automate insulin delivery for Type 1 diabetics.
Sanofi’s experimental diabetes drug U300 helped control glucose with fewer patients experiencing incidents of dangerously low blood-sugar levels at night than the company’s Lantus in two clinical trials.
GlaxoSmithKline Plc’s experimental diabetes medicine albiglutide lowered blood sugar better than Merck & Co.’s Januvia or Sanofi’s Amaryl, while more patients reported gastrointestinal side effects, in a study.
Zafgen Inc., a closely held developer of an experimental drug for obesity, said its therapy yielded weight loss of as much as 10 kilograms (22 pounds) in three months, an early look at study results showed.